Sprint Bioscience AB
STO:SPRINT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sprint Bioscience AB
Other Non-Cash Items
Sprint Bioscience AB
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sprint Bioscience AB
STO:SPRINT
|
Other Non-Cash Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Other Non-Cash Items
kr8.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Other Non-Cash Items
kr35.6m
|
CAGR 3-Years
51%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Other Non-Cash Items
kr5.4B
|
CAGR 3-Years
308%
|
CAGR 5-Years
271%
|
CAGR 10-Years
N/A
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Other Non-Cash Items
kr975m
|
CAGR 3-Years
46%
|
CAGR 5-Years
84%
|
CAGR 10-Years
52%
|
|
|
BioArctic AB
STO:BIOA B
|
Other Non-Cash Items
kr24.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sprint Bioscience AB
Glance View
Sprint Bioscience AB is a pharmaceutical company, which engages in the research and development of drug for cancer. The company is headquartered in Huddinge, Stockholm. The company went IPO on 2014-11-07. The company is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The firm's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.
